Felix Kiecker

4.5k total citations
48 papers, 1.4k citations indexed

About

Felix Kiecker is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Felix Kiecker has authored 48 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 19 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in Felix Kiecker's work include Cutaneous Melanoma Detection and Management (15 papers), Melanoma and MAPK Pathways (13 papers) and Polyomavirus and related diseases (10 papers). Felix Kiecker is often cited by papers focused on Cutaneous Melanoma Detection and Management (15 papers), Melanoma and MAPK Pathways (13 papers) and Polyomavirus and related diseases (10 papers). Felix Kiecker collaborates with scholars based in Germany, United States and France. Felix Kiecker's co-authors include Célèste Lebbé, Maja A. Hofmann, Jean‐Jacques Grob, Rudolf Volkmer, Hans‐Dieter Volk, Florian Kern, Sandra P. D’Angelo, Patrick Terheyden, Dirk Schadendorf and Uwe Trefzer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Infectious Diseases.

In The Last Decade

Felix Kiecker

47 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Felix Kiecker Germany 19 837 405 330 324 282 48 1.4k
Juergen C. Becker Germany 15 941 1.1× 412 1.0× 91 0.3× 542 1.7× 381 1.4× 18 1.4k
Toshiya Shinohara Japan 26 1.0k 1.2× 647 1.6× 249 0.8× 501 1.5× 104 0.4× 83 2.4k
Jeffrey P. North United States 23 1.5k 1.7× 1.1k 2.7× 294 0.9× 444 1.4× 140 0.5× 93 2.5k
Ann W. Silk United States 24 1.3k 1.6× 576 1.4× 234 0.7× 656 2.0× 77 0.3× 89 2.0k
Aude G. Chapuis United States 22 1.4k 1.7× 310 0.8× 243 0.7× 832 2.6× 382 1.4× 75 2.1k
Alice Chuang United States 22 446 0.5× 871 2.2× 364 1.1× 119 0.4× 119 0.4× 29 1.6k
Patrick Terheyden Germany 23 2.8k 3.3× 606 1.5× 398 1.2× 815 2.5× 813 2.9× 107 3.4k
Sandra Richman United States 12 1.4k 1.6× 137 0.3× 214 0.6× 370 1.1× 541 1.9× 21 2.1k
Gerald Willimsky Germany 23 981 1.2× 638 1.6× 82 0.2× 1.2k 3.8× 67 0.2× 49 2.0k
Mounir Trimèche Tunisia 24 438 0.5× 631 1.6× 153 0.5× 118 0.4× 37 0.1× 72 1.3k

Countries citing papers authored by Felix Kiecker

Since Specialization
Citations

This map shows the geographic impact of Felix Kiecker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Kiecker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Kiecker more than expected).

Fields of papers citing papers by Felix Kiecker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix Kiecker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Kiecker. The network helps show where Felix Kiecker may publish in the future.

Co-authorship network of co-authors of Felix Kiecker

This figure shows the co-authorship network connecting the top 25 collaborators of Felix Kiecker. A scholar is included among the top collaborators of Felix Kiecker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix Kiecker. Felix Kiecker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
D’Angelo, Sandra P., Célèste Lebbé, Laurent Mortier, et al.. (2024). First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study. ESMO Open. 9(5). 103461–103461. 9 indexed citations
2.
Berking, Carola, Elisabeth Livingstone, Dirk Debus, et al.. (2023). COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers. 15(18). 4436–4436. 2 indexed citations
3.
Navrazhina, Kristina, Sandra Garcet, Samuel C. Williams, et al.. (2023). Laser capture microdissection provides a novel molecular profile of human primary cutaneous melanoma. Pigment Cell & Melanoma Research. 37(1). 81–89.
4.
5.
D’Angelo, Sandra P., Célèste Lebbé, Laurent Mortier, et al.. (2021). First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. Journal for ImmunoTherapy of Cancer. 9(7). e002646–e002646. 80 indexed citations
6.
Stege, Henner, Maximilian Haist, Peter Mohr, et al.. (2021). Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. Cancer Immunology Immunotherapy. 70(11). 3313–3322. 17 indexed citations
7.
Gambichler, Thilo, Felix Kiecker, Uwe Reinhold, et al.. (2020). Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I–III patients. European Journal of Cancer. 143. 11–18. 9 indexed citations
8.
Hauschild, Axel, Paolo A. Ascierto, Dirk Schadendorf, et al.. (2020). Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. European Journal of Cancer. 125. 114–120. 50 indexed citations
9.
Robert, Caroline, Keith T. Flaherty, Paul Nathan, et al.. (2019). Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma. European Journal of Cancer. 109. 61–69. 54 indexed citations
10.
11.
Bartels, Frederik, et al.. (2019). Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Annals of Oncology. 30(5). 823–829. 33 indexed citations
12.
Yan, Bernice Y., Sandra Garcet, Nicholas Gulati, et al.. (2018). Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. Experimental Dermatology. 28(1). 35–44. 18 indexed citations
13.
Kiecker, Felix, et al.. (2018). Crucial role of reactive oxygen species (ROS) for the proapoptotic effects of indirubin derivative DKP‐073 in melanoma cells. Molecular Carcinogenesis. 58(2). 258–269. 16 indexed citations
14.
15.
Kiecker, Felix, et al.. (2007). Large primary meningeal melanoma in an adult patient with neurocutaneous melanosis. Clinical Neurology and Neurosurgery. 109(5). 448–451. 8 indexed citations
16.
Trefzer, Uwe, Gunda Herberth, Maja A. Hofmann, et al.. (2006). The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma. BMC Cancer. 6(1). 8–8. 10 indexed citations
17.
Jochmann, Nicoline, Felix Kiecker, Adrian C. Borges, et al.. (2005). Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovascular Ultrasound. 3(1). 26–26. 24 indexed citations
18.
Hofmann, Maja A., Felix Kiecker, Reinhard Würm, et al.. (2005). Temozolomide With or Without Radiotherapy in Melanoma With Unresectable Brain Metastases. Journal of Neuro-Oncology. 76(1). 59–64. 55 indexed citations
19.
Hoffmeister, Bodo, Felix Kiecker, Elham Khatamzas, et al.. (2003). Evaluation of the Frequency of Virus-Specific CD8+ T Cells by Cytokine Flow Cytometry. Humana Press eBooks. 215. 59–70. 1 indexed citations
20.
Kern, Florian, Felix Kiecker, Elham Khatamzas, et al.. (2002). Cytomegalovirus (CMV) Phosphoprotein 65 Makes a Large Contribution to Shaping the T Cell Repertoire in CMV‐Exposed Individuals. The Journal of Infectious Diseases. 185(12). 1709–1716. 215 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juergen C. Becker Breakdown of academic impact, for papers by Toshiya Shinohara Breakdown of academic impact, for papers by Jeffrey P. North Breakdown of academic impact, for papers by Ann W. Silk Breakdown of academic impact, for papers by Aude G. Chapuis Breakdown of academic impact, for papers by Alice Chuang Breakdown of academic impact, for papers by Patrick Terheyden Breakdown of academic impact, for papers by Sandra Richman Breakdown of academic impact, for papers by Gerald Willimsky Breakdown of academic impact, for papers by Mounir Trimèche
Rankless by CCL
2026